New research reveals that semaglutide significantly improves liver health in MASH patients. A new study published in the New England Journal of Medicine reveals that semaglutide significantly improves outcomes for patients with a serious form of liver disease, benefiting approximately two-thirds of those treated. The findings come from the ESSENCE phase 3 clinical trial, a [...]from SciTechDaily https://ift.tt/deThl8E
